Inflammatory bowel disease is a lifelong condition. The decisions made in the first two to three years of diagnosis, about which medication class to use, whether biologics should be introduced early or reserved, how aggressively to treat endoscopic disease versus symptoms alone, and when surgery becomes appropriate, have consequences that extend for decades.
For international patients who are uncertain whether their current treatment is optimised for their disease pattern, or who have not yet achieved remission after multiple therapy changes, a second opinion from an IBD specialist in India can change the treatment trajectory in ways that matter long-term. Inflammatory bowel disease (IBD) treatment in India is now delivered at world-standard quality at India's leading NABH and JCI-accredited gastroenterology hospitals, at costs that are 60 to 80 percent lower than Western equivalents.
When a Second Opinion for IBD Is Warranted
Most patients with IBD tolerate their diagnosis and its management, but many continue on suboptimal treatment for years without knowing it. A second opinion is worth seeking when:
-
Symptoms persist despite one or more medication changes.
-
Biologics have not been discussed despite steroid-dependent disease lasting more than three months.
-
There is uncertainty about whether the diagnosis is Crohn's disease or ulcerative colitis, as treatment pathways differ significantly.
-
A surgical recommendation has been made and the patient wants to confirm it is the right next step.
-
IBD was diagnosed based on symptoms alone without colonoscopy with biopsy confirming histology.
-
Fistulising or perianal Crohn's disease has not responded to the current approach.
-
The patient is considering pregnancy and needs updated guidance on medication safety.
-
Therapeutic drug monitoring (measuring biologic drug levels in blood) has never been performed despite biologic use.
A second opinion does not require discarding the existing treatment relationship. It is an additional perspective from a specialist who may identify something the current team has not, or confirm that the current approach is correct, both of which are valuable.
Understanding IBD: Crohn's Disease and Ulcerative Colitis
IBD is a group of chronic inflammatory conditions of the gastrointestinal tract. The two main forms are Crohn's disease and ulcerative colitis (UC), which differ in distribution, depth of inflammation, and treatment response.
Crohn's Disease
Crohn's disease can affect any part of the digestive tract from mouth to anus, with skip lesions and transmural inflammation. Key features:
-
Abdominal pain, diarrhoea, weight loss, fatigue.
-
Perianal disease including fistulas and abscesses in 25 to 30 percent of patients.
-
Strictures and bowel obstruction in long-standing disease.
-
Extraintestinal manifestations including joint disease, eye inflammation, and skin lesions.
Surgery for Crohn's disease addresses complications but does not cure the underlying condition. Post-surgical recurrence is common without prophylactic medical treatment.
Ulcerative Colitis
UC is confined to the colon and rectum with continuous mucosal inflammation. Key features:
-
Bloody diarrhoea and urgency as hallmark symptoms.
-
Disease extent ranges from proctitis (rectal-only) to pancolitis (entire colon).
-
Colectomy is curative for UC but carries significant functional consequences.
-
Colorectal cancer risk increases with disease duration, requiring surveillance colonoscopy.
The Modern Treatment Ladder for IBD: What India's Specialists Offer
IBD treatment has been transformed by the development of biologic therapies and small molecule drugs. India's gastroenterology centres apply the full modern treatment ladder.
Step 1: Conventional Therapy
-
5-aminosalicylates (mesalazine, sulfasalazine): First-line for mild to moderate UC. Less effective for Crohn's disease.
-
Corticosteroids (prednisolone, budesonide): For induction of remission in flares. Not appropriate for maintenance therapy.
-
Immunomodulators (azathioprine, 6-mercaptopurine, methotrexate): Maintain remission and reduce steroid dependence. Require regular blood monitoring for toxicity.
Step 2: Biologic Therapy
Biologics target specific immune pathways driving inflammation. The key agents available in India include:
| Biologic class | Agents | Approved for |
|---|---|---|
| Anti-TNF | Infliximab, adalimumab | Crohn's disease, UC |
| Anti-integrin | Vedolizumab | Crohn's disease, UC |
| Anti-IL-12/23 | Ustekinumab | Crohn's disease, UC |
| Anti-IL-23 | Risankizumab | Crohn's disease |
Biosimilar versions of infliximab and adalimumab are available in India at dramatically lower costs than originator brands, making biologic therapy financially accessible for international patients who would not otherwise afford it. A biosimilar infliximab infusion in India costs approximately Rs. 8,000 to Rs. 20,000 (USD 96 to USD 240) per infusion versus USD 3,000 to USD 8,000 in the USA.
Ustekinumab and vedolizumab, which showed significant clinical remission rates in Crohn's disease and UC respectively in systematic review data, are available at India's leading IBD centres.
Step 3: Small Molecule Therapies
Small molecule drugs taken orally represent the newest class in IBD treatment:
-
Tofacitinib: JAK inhibitor approved for UC, producing rapid symptom relief.
-
Filgotinib and upadacitinib: Selective JAK1 inhibitors with favourable safety profiles for both UC and Crohn's disease.
-
Ozanimod: Sphingosine-1-phosphate receptor modulator for UC. These agents are available at India's academic IBD centres for patients with moderate to severe disease who have failed conventional and biologic therapy.
Step 4: Therapeutic Drug Monitoring
One of the most consistently under-used tools in IBD management is therapeutic drug monitoring (TDM): measuring the blood level of the biologic drug and antibodies against it. When a biologic loses effectiveness, TDM identifies whether this is due to:
-
Insufficient drug levels: correctable by increasing the dose or frequency.
-
Development of anti-drug antibodies: indicating a switch to a different biologic class.
India's IBD centres perform TDM as a standard part of biologic management, allowing treatment to be optimised rather than abandoned prematurely.
Step 5: Faecal Microbiota Transplantation (FMT)
FMT is approved for recurrent Clostridioides difficile infection and is being investigated for UC. Select Indian tertiary gastroenterology centres offer FMT within structured research and clinical programmes for UC patients not adequately controlled by conventional treatment.
Step 6: Surgery
Surgery is indicated for UC when medical therapy fails to achieve adequate disease control, when complications arise, or for cancer prevention in long-standing extensive colitis. For Crohn's disease, surgery addresses specific complications including obstruction, fistula, abscess, and severe perianal disease. Minimally invasive laparoscopic colectomy and ileocolic resection are available at India's leading colorectal surgery centres.
What a Second Opinion for IBD in India Involves
A second opinion gastroenterology consultation in India covers:
-
Full review of prior colonoscopy and histology reports.
-
Review of all imaging including CT enterography and MRI enterography for Crohn's.
-
Assessment of current medication doses, duration, and therapeutic drug levels where biologic therapy is in use.
-
Confirming disease classification (Montreal classification for extent and behaviour).
-
Disease activity scoring (Harvey-Bradshaw Index for Crohn's, Mayo Score for UC).
-
Recommending any missing investigations including video capsule endoscopy for small bowel Crohn's.
-
Proposing a treatment change or confirming the current approach is optimal.
Before traveling, send the following to Karetrip for pre-assessment:
-
All colonoscopy reports with histology from the past three years.
-
CT or MRI enterography reports and images.
-
Current medication list with doses and duration.
-
Most recent blood results including full blood count, CRP, albumin, faecal calprotectin.
-
Biologic drug level and antibody results if performed.
Top Gastroenterology Centres for IBD Treatment in India
India's leading IBD centres are concentrated in Delhi, Mumbai, Chennai, Bangalore, and Kolkata, with dedicated IBD clinics at major NABH and JCI-accredited hospitals:
-
Apollo Hospitals (multiple cities): Dedicated IBD programme, biologic infusion centre, full endoscopy suite.
-
Fortis Memorial Research Institute, Gurgaon: Academic IBD programme with advanced imaging.
-
Max Healthcare, Delhi: Dedicated IBD team, therapeutic drug monitoring, FMT programme.
-
Manipal Hospitals: IBD centres across multiple cities including Kolkata (Dhakuria), Bangalore, and Mumbai.
-
AIIMS, Delhi: Public sector academic centre with the most comprehensive IBD research programme in India.
Cost of IBD Treatment in India for International Patients
| Item | India cost | USA equivalent |
|---|---|---|
| IBD second opinion consultation | Rs. 1,500 to Rs. 3,000 (USD 18 to USD 36) | USD 300 to USD 600 |
| Colonoscopy with biopsy | Rs. 5,000 to Rs. 12,000 (USD 60 to USD 145) | USD 2,000 to USD 4,000 |
| Biosimilar infliximab infusion | Rs. 8,000 to Rs. 20,000 (USD 96 to USD 240) | USD 3,000 to USD 8,000 |
| Ustekinumab injection | Rs. 25,000 to Rs. 50,000 (USD 300 to USD 600) | USD 5,000 to USD 12,000 |
| Faecal calprotectin test | Rs. 1,500 to Rs. 3,000 (USD 18 to USD 36) | USD 200 to USD 400 |
| Therapeutic drug monitoring | Rs. 3,000 to Rs. 6,000 (USD 36 to USD 72) | USD 500 to USD 1,500 |
How Karetrip Connects International IBD Patients to the Right Specialist in India
Karetrip reviews each patient's existing colonoscopy reports, imaging, medication history, and investigation results before recommending an IBD specialist in India, ensuring the proposed gastroenterologist has specific IBD subspecialty experience and access to the full therapeutic range the patient's case may require.
From pre-travel record review and medical visa coordination, through accommodation near the treating hospital and discharge documentation for continued IBD management at home, Karetrip manages the complete international patient journey for IBD treatment in India.
Chat with our Medical care assistant, RUA, for quick guidance and support and take the first step toward a second opinion that may change your IBD treatment trajectory.
Medical Disclaimer
This article is for informational purposes only and does not constitute medical advice. IBD management requires evaluation by a qualified gastroenterologist or IBD specialist. Do not change or stop medication without consulting your treating doctor.